Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats - PubMed (original) (raw)
Comparative Study
Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats
T Ochiai et al. Transplantation. 1987 Dec.
Abstract
Immunosuppressive activities of the newly discovered FK506, isolated from Streptomyces tsukubaensis, were examined by using cardiac allotransplantation in the rat, and the mechanisms underlying induction and maintenance of FK506-induced long-term allograft survival were studied. Male rats of WKA (RT1k) and F344 (RT1lvl) strains were used as recipients and donors, respectively, and those of BN (RT1n) strain were used as third-party donors. Treatment with FK506, beginning from the day of allografting for 14, 10, or as few as 4 days, prolonged allograft survival significantly across the major histocompatibility barrier. The minimum doses for prolonging graft survival were 0.1 mg/kg/day by intramuscular treatment and 1.0 mg/kg/day by oral treatment. Treatment with FK506 at a dose of 0.32 mg/kg/day from day 4 until day 10 resulted in all the grafts surviving indefinitely and from days 5 to 10, half the grafts survived indefinitely, suggesting that the agent inhibited ongoing rejection. On the other hand, cyclosporine treatment at a dose of 20 mg/kg/day from day 2 did not prolong graft survival time statistically significantly. Induction of prolonged graft survival was not obtained by pretreatment of the prospective donor or recipient; prolonging effects were observed only when the agent was administered after allografting. Thus, the primary effect of the agent is exerted on responder lymphocytes reacting to the donor antigens in the induction phase of long-term graft acceptance. The mechanisms underlying the maintenance of long-term grafts were analyzed by testing the capacity of lymphocytes or serum of long-term graft-bearing rats to inhibit graft rejection in irradiated grafted hosts. Transfer of 2 x 10(8) lymphocytes from FK506-induced long-term F344 graft-bearing WKA rats resulted in indefinite survival of F344 heart allografts, but it did not prolong survival of third-party BN hearts. Transfer of 2.5 ml serum from long-term graft-bearing rats also prolonged graft survival of F344 hearts, but not BN hearts. These results suggest that donor strain-specific suppressor cells and humoral factor(s) are induced by treatment with FK506 in the presence of allografts, and that they play at least partial roles in the maintenance of long-term allograft acceptance.
Similar articles
- Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506.
Inamura N, Nakahara K, Kino T, Goto T, Aoki H, Yamaguchi I, Kohsaka M, Ochiai T. Inamura N, et al. Transplantation. 1988 Jan;45(1):206-9. doi: 10.1097/00007890-198801000-00042. Transplantation. 1988. PMID: 2447690 - Effect of donor-specific splenocytes via portal vein and FK506 in rat small bowel transplantation.
Miyauchi T, Ishikawa M, Tashiro S, Hisaeda H, Nagasawa H, Himeno K. Miyauchi T, et al. Transplantation. 1998 Jan 15;65(1):27-32. doi: 10.1097/00007890-199801150-00006. Transplantation. 1998. PMID: 9448139 - Graft persistence effectively induces and maintains donor-specific unresponsiveness.
Nishinaka H, Nakafusa Y, Hirano T, Takeda K, Kawano R, Nakano M, Arima T, Nakamura K, Kamei T, Tanaka M. Nishinaka H, et al. J Surg Res. 1997 Mar;68(2):145-52. doi: 10.1006/jsre.1997.5053. J Surg Res. 1997. PMID: 9184673 - [Discovery and development of a novel immunosuppressant, tacrolimus hydrate].
Tanaka H, Nakahara K, Hatanaka H, Inamura N, Kuroda A. Tanaka H, et al. Yakugaku Zasshi. 1997 Aug;117(8):542-54. doi: 10.1248/yakushi1947.117.8_542. Yakugaku Zasshi. 1997. PMID: 9306728 Review. Japanese. - [Immunosuppressive activity of a microbial product].
Hatanaka H, Shimomura K. Hatanaka H, et al. Nihon Yakurigaku Zasshi. 1997 Oct;110 Suppl 1:69P-74P. doi: 10.1254/fpj.110.supplement_69. Nihon Yakurigaku Zasshi. 1997. PMID: 9503409 Review. Japanese.
Cited by
- Structure-Guided Synthesis of FK506 and FK520 Analogs with Increased Selectivity Exhibit In Vivo Therapeutic Efficacy against Cryptococcus.
Hoy MJ, Park E, Lee H, Lim WY, Cole DC, DeBouver ND, Bobay BG, Pierce PG, Fox D 3rd, Ciofani M, Juvvadi PR, Steinbach W, Hong J, Heitman J. Hoy MJ, et al. mBio. 2022 Jun 28;13(3):e0104922. doi: 10.1128/mbio.01049-22. Epub 2022 May 23. mBio. 2022. PMID: 35604094 Free PMC article. - Neuroimmune interactions and immunoengineering strategies in peripheral nerve repair.
Wofford KL, Shultz RB, Burrell JC, Cullen DK. Wofford KL, et al. Prog Neurobiol. 2022 Jan;208:102172. doi: 10.1016/j.pneurobio.2021.102172. Epub 2021 Sep 4. Prog Neurobiol. 2022. PMID: 34492307 Free PMC article. Review. - Transplantation tolerance and its outcome during infections and inflammation.
Chong AS, Alegre ML. Chong AS, et al. Immunol Rev. 2014 Mar;258(1):80-101. doi: 10.1111/imr.12147. Immunol Rev. 2014. PMID: 24517427 Free PMC article. Review. - Immunosuppressant discovery from Tripterygium wilfordii Hook f: the novel triptolide analog (5R)-5-hydroxytriptolide (LLDT-8).
Tang W, Zuo JP. Tang W, et al. Acta Pharmacol Sin. 2012 Sep;33(9):1112-8. doi: 10.1038/aps.2012.108. Epub 2012 Aug 27. Acta Pharmacol Sin. 2012. PMID: 22922344 Free PMC article. Review. - Preventive effect of FK 506 (tacrolimus hydrate) on experimentally induced acute liver injury in rats.
Uchida K, Sakaida I, Hironaka K, Kayano K, Okita K. Uchida K, et al. Dig Dis Sci. 2000 Oct;45(10):1996-2001. doi: 10.1023/a:1005698818891. Dig Dis Sci. 2000. PMID: 11117573
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical